drugset / Trial / NCT00043576
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
RandomizedParallel-groupDouble-blindTreatment
Summary
The purposes of this study are to determine if DN-101 plus Taxotere lowers PSA levels, delays or limits disease progression and is safe with minimal side effects.
Timeline
- Start
- 2002-08
- Primary completion
- —
- Completion
- 2005-12
Publications
- Background Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer. 2001 Jun 15;91(12):2431-9.
- Background Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003 Jan 1;21(1):123-8. doi: 10.1200/jco.2003.05.117.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcitriol | Small molecule | — | — |
| Background | Docetaxel | Small molecule | — | — |